Northland Securities analyst Carl Byrnes maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $35.00. The company’s shares closed last Monday at $11.37.
According to TipRanks.com, Byrnes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.5% and a 35.5% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Opiant Pharmaceuticals, and Aridis Pharmaceuticals.
Flexion Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $22.60, which is a 98.1% upside from current levels. In a report issued on May 26, Guggenheim also initiated coverage with a Buy rating on the stock with a $20.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.98 and a one-year low of $5.01. Currently, Flexion Therapeutics has an average volume of 982.6K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FLXN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.
